Seres doubles down on a microbiome do-over as the FDA clears a make-or-break study

Seres doubles down on a microbiome do-over as the FDA clears a make-or-break study

Submitted by admin on March 16, 2017 - 9:49am
Source: 
Endpoints
News Tags: 
Seres Therapeutics
microbiome
FDA
clinical trials
SER-109
Headline: 
Seres doubles down on a microbiome do-over as the FDA clears a make-or-break study

Do Not Allow Advertisers to Use My Personal information